Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

The company has two approved drugs on the market. The first is Auryxia (ferric citrate) for the treatment of hyperphosphatemia (HP) and iron deficiency anemia (IDA). In January 2025, the company ...